Analysts Project Treace Medical Q1 Revenue Significantly Below Guidance, Expecting 31-Cent Loss
summarizeSummary
Analysts are forecasting Treace Medical Concepts to report a Q1 2026 loss of 31 cents per share and a 12.6% year-over-year revenue decrease to $45.96 million. This revenue estimate is notably below the company's own guidance of $79.399 million, which was issued on February 27, 2026, coinciding with the 10-K filing that confirmed widening net losses. The significant discrepancy between analyst expectations and company guidance suggests a potential material earnings miss or a sharp downward revision in market sentiment regarding the company's near-term performance. This divergence is a critical piece of new information for traders and could lead to substantial stock price volatility when actual results are reported on May 8.
At the time of this announcement, TMCI was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.8M. The 52-week trading range was $1.17 to $7.78. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.